Loading clinical trials...
Loading clinical trials...
SNIFF Multi-Device Study 2 - Study of Nasal Insulin to Fight Forgetfulness
Conditions
Interventions
20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
Locations
1
United States
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
Start Date
July 16, 2020
Primary Completion Date
November 3, 2020
Completion Date
November 3, 2020
Last Updated
April 2, 2026
NCT06223672
NCT07101380
NCT06121544
NCT07504276
NCT06395558
NCT07484048
Lead Sponsor
Wake Forest University Health Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions